Prop 65
Three supplement ingredients - DHEA, androstenedione and Tribulus Terrestris - are challenged under California Proposition 65 by a group called Consumer Cause, represented by Los Angeles attorney Morse Mehrban. Consumer Cause charges the three ingredients expose consumers to "testosterone and its esters." In a June 27 letter to California Deputy Attorney General Ed Weil, NNFA and CRN say the notices of intent to sue are "invalid and should be retracted." The ingredients cannot expose consumers to testosterone as humans possess testosterone in their bodies naturally, the groups state, adding none of the ingredients contain testosterone. To date, the group has filed no lawsuits
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.